Market Overview

Janney, Morgan Stanley Say Sarepta's Gene Therapy Remains On Track

Janney, Morgan Stanley Say Sarepta's Gene Therapy Remains On Track
Related SRPT
Lennar, Sarepta, US Steel, IWM: 'Fast Money' Picks For January 11
The Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering
FDA to beef up cell and gene therapy staff (Seeking Alpha)

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares were under pressure this week following a regulatory update that analysts say may have been misunderstood by the market. 

Sarepta shares were down 5 percent at the start of the week against a biotech index that was up 3 percent after the company provided an update on its microdystrophin gene therapy program that investors perceived as being different from what had previously been expected.

The Analysts

Janney analyst Yun Zhong reiterated a Buy rating on Sarepta with a $200 fair value estimate. 

Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating with a $161 price target. 

The Thesis 

In a follow-up discussion with Janney, Sarepta clarified that the pathway for regulatory approval of the new therapy remains the same as what the company had previously indicated and reiterated that a U.S. launch by the end of 2020 remains possible based on positive data from clinical studies, Zhong said in a Tuesday note. 

“Sarepta's active and ambitious pipeline building is on track,” the analyst said. “We continue to see significant upside potential in Sarepta's gene therapy pipeline.”

Janney also pointed out other positives for Sarepta, including that it continues to build manufacturing capacity.

Harrison said Morgan Stanley also didn’t see the announcement that the therapy would require an additional registration study as a significant d from previously announced timelines.

Price Action

Sarepta shares were up 0.22 percent at $110.26 at the time of publication. 

Related Links

Credit Suisse Joins Consensus To Prescribe Sarepta

Morgan Stanley Buys Into Sarepta Amid Sell-Off, Sees $600M Recurring Opportunity In DMD Candidate

Latest Ratings for SRPT

Nov 2018CitigroupMaintainsBuyBuy
Oct 2018BernsteinInitiates Coverage OnOutperform
Oct 2018Cantor FitzgeraldInitiates Coverage OnOverweight

View More Analyst Ratings for SRPT
View the Latest Analyst Ratings

Posted-In: Janney Matthew HarrisonAnalyst Color Biotech Price Target Reiteration Analyst Ratings General Best of Benzinga


Related Articles (SRPT)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

S&P 500 Companies On Track For Double-Digit Earnings Growth, Despite Apple Disappointment

'Halftime Report' Picks For January 8: Amarin, Apple And More